Loading…
Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers
Purpose: Amplification of chromosomal region 20q13 occurs in breast cancer but remains poorly characterized. Experimental Design: To establish the frequency of 20q13 amplification and select the amplified cases to be studied, we used fluorescence in situ hybridization of bacterial artificial chromos...
Saved in:
| Published in: | Clinical cancer research 2006-08, Vol.12 (15), p.4533-4544 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c483t-457f6ff54168e139e6fd9d5a0b5d3c894164cfb35b9f451de484667af98cc4793 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c483t-457f6ff54168e139e6fd9d5a0b5d3c894164cfb35b9f451de484667af98cc4793 |
| container_end_page | 4544 |
| container_issue | 15 |
| container_start_page | 4533 |
| container_title | Clinical cancer research |
| container_volume | 12 |
| creator | GINESTIER, Christophe CERVERA, Nathalie CHAFFANET, Max BIMBAUM, Daniel BERTUCCI, Francois FINETTI, Pascal ESTEYRIES, Séverine ESTERNI, Benjamin ADDLAIDE, José XERRI, Luc VIENS, Patrice JACQUEMIER, Jocelyne CHARAFE-JAUFFRET, Emmanuelle |
| description | Purpose: Amplification of chromosomal region 20q13 occurs in breast cancer but remains poorly characterized.
Experimental Design: To establish the frequency of 20q13 amplification and select the amplified cases to be studied, we used fluorescence in situ hybridization of bacterial artificial chromosome probes for three 20q13 loci ( MYBL2, STK6, ZNF217 ) on sections of tissue microarrays containing 466 primary carcinoma samples. We used Affymetryx whole-genome DNA microarrays
to establish the gene expression profiles of 20q13-amplified tumors and quantitative reverse transcription-PCR to validate
the results.
Results: We found 36 (8%) 20q13-amplified samples. They were distributed in two types: type 1 tumors showed ZNF217 amplification only, whereas type 2 tumors showed amplification at two or three loci. Examination of the histoclinical features
of the amplified tumors showed two strikingly opposite data. First, type 1 tumors were more frequently lymph node–negative
tumors but were paradoxically associated with a poor prognosis. Second, type 2 tumors were more frequently lymph node–positive
tumors but were paradoxically associated with a good prognosis. Type 1 and type 2 showed different gene expression profiles.
No 20q13 gene could be associated with type 1 amplification, whereas several 20q13 genes were overexpressed in type 2 tumors.
Conclusions: Our results suggest that amplified tumors of types 1 and 2 are two distinct entities resulting from two different mechanisms
and associated to different prognosis. |
| doi_str_mv | 10.1158/1078-0432.CCR-05-2339 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01431971v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68734669</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-457f6ff54168e139e6fd9d5a0b5d3c894164cfb35b9f451de484667af98cc4793</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi1UREvhEYpyAYlDWk_GTuzjNiptpZVAFZwtrzPedZVNtvZuC2-Pwy6UW08zGn8znvl_xs6AnwNIdQG8USUXWJ237V3JZVkh6lfsBKRsSqxqeZTzv8wxe5vSPecggIs37BhqpbXU-oTdfovjchhTSIUduuKaBiqufm4ipRTGocivPvRhWBajLyr-AFjO1ps--EBdcRnJpm3R2sFRTO_Ya2_7RO8P8ZT9-HL1vb0p51-vb9vZvHRC4bYUsvG191LkHQhQU-073UnLF7JDp3SuC-cXKBfaCwkdCSXqurFeK-dEo_GUfd7PXdnebGJY2_jLjDaYm9ncTLV8JYJu4BEy-2nPbuL4sKO0NeuQHPW9HWjcJVOrBvN0_SIIWteNEphBuQddHFOK5P-tANxMxphJdDOJbrIxhkszGZP7Phw-2C3W1D13HZzIwMcDYJOzvY9Z1ZCeOcWxqhT-d35Yrp5CJOP-6J8dIxvdykBlQBohEfE3PYGhyQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19967843</pqid></control><display><type>article</type><title>Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers</title><source>Freely Accessible Journals</source><creator>GINESTIER, Christophe ; CERVERA, Nathalie ; CHAFFANET, Max ; BIMBAUM, Daniel ; BERTUCCI, Francois ; FINETTI, Pascal ; ESTEYRIES, Séverine ; ESTERNI, Benjamin ; ADDLAIDE, José ; XERRI, Luc ; VIENS, Patrice ; JACQUEMIER, Jocelyne ; CHARAFE-JAUFFRET, Emmanuelle</creator><creatorcontrib>GINESTIER, Christophe ; CERVERA, Nathalie ; CHAFFANET, Max ; BIMBAUM, Daniel ; BERTUCCI, Francois ; FINETTI, Pascal ; ESTEYRIES, Séverine ; ESTERNI, Benjamin ; ADDLAIDE, José ; XERRI, Luc ; VIENS, Patrice ; JACQUEMIER, Jocelyne ; CHARAFE-JAUFFRET, Emmanuelle</creatorcontrib><description>Purpose: Amplification of chromosomal region 20q13 occurs in breast cancer but remains poorly characterized.
Experimental Design: To establish the frequency of 20q13 amplification and select the amplified cases to be studied, we used fluorescence in situ hybridization of bacterial artificial chromosome probes for three 20q13 loci ( MYBL2, STK6, ZNF217 ) on sections of tissue microarrays containing 466 primary carcinoma samples. We used Affymetryx whole-genome DNA microarrays
to establish the gene expression profiles of 20q13-amplified tumors and quantitative reverse transcription-PCR to validate
the results.
Results: We found 36 (8%) 20q13-amplified samples. They were distributed in two types: type 1 tumors showed ZNF217 amplification only, whereas type 2 tumors showed amplification at two or three loci. Examination of the histoclinical features
of the amplified tumors showed two strikingly opposite data. First, type 1 tumors were more frequently lymph node–negative
tumors but were paradoxically associated with a poor prognosis. Second, type 2 tumors were more frequently lymph node–positive
tumors but were paradoxically associated with a good prognosis. Type 1 and type 2 showed different gene expression profiles.
No 20q13 gene could be associated with type 1 amplification, whereas several 20q13 genes were overexpressed in type 2 tumors.
Conclusions: Our results suggest that amplified tumors of types 1 and 2 are two distinct entities resulting from two different mechanisms
and associated to different prognosis.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-05-2339</identifier><identifier>PMID: 16899599</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms - surgery ; Cancer ; Cellular Biology ; chromosome 20 ; Chromosomes, Human, Pair 20 - genetics ; Cluster Analysis ; DNA microarrays ; Female ; Gene Amplification ; Gene Expression Profiling ; Gynecology. Andrology. Obstetrics ; Humans ; In Situ Hybridization, Fluorescence ; Kaplan-Meier Estimate ; Life Sciences ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Oligonucleotide Array Sequence Analysis - methods ; Pharmacology. Drug treatments ; Prognosis ; Reverse Transcriptase Polymerase Chain Reaction - methods ; Survival Rate ; Tissue Array Analysis - methods ; Treatment Outcome ; Tumors</subject><ispartof>Clinical cancer research, 2006-08, Vol.12 (15), p.4533-4544</ispartof><rights>2006 INIST-CNRS</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-457f6ff54168e139e6fd9d5a0b5d3c894164cfb35b9f451de484667af98cc4793</citedby><cites>FETCH-LOGICAL-c483t-457f6ff54168e139e6fd9d5a0b5d3c894164cfb35b9f451de484667af98cc4793</cites><orcidid>0000-0002-2674-3123 ; 0000-0002-7477-3837 ; 0000-0002-0157-0959 ; 0000-0002-0286-1299 ; 0000-0002-2344-1488</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18032283$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16899599$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01431971$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>GINESTIER, Christophe</creatorcontrib><creatorcontrib>CERVERA, Nathalie</creatorcontrib><creatorcontrib>CHAFFANET, Max</creatorcontrib><creatorcontrib>BIMBAUM, Daniel</creatorcontrib><creatorcontrib>BERTUCCI, Francois</creatorcontrib><creatorcontrib>FINETTI, Pascal</creatorcontrib><creatorcontrib>ESTEYRIES, Séverine</creatorcontrib><creatorcontrib>ESTERNI, Benjamin</creatorcontrib><creatorcontrib>ADDLAIDE, José</creatorcontrib><creatorcontrib>XERRI, Luc</creatorcontrib><creatorcontrib>VIENS, Patrice</creatorcontrib><creatorcontrib>JACQUEMIER, Jocelyne</creatorcontrib><creatorcontrib>CHARAFE-JAUFFRET, Emmanuelle</creatorcontrib><title>Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: Amplification of chromosomal region 20q13 occurs in breast cancer but remains poorly characterized.
Experimental Design: To establish the frequency of 20q13 amplification and select the amplified cases to be studied, we used fluorescence in situ hybridization of bacterial artificial chromosome probes for three 20q13 loci ( MYBL2, STK6, ZNF217 ) on sections of tissue microarrays containing 466 primary carcinoma samples. We used Affymetryx whole-genome DNA microarrays
to establish the gene expression profiles of 20q13-amplified tumors and quantitative reverse transcription-PCR to validate
the results.
Results: We found 36 (8%) 20q13-amplified samples. They were distributed in two types: type 1 tumors showed ZNF217 amplification only, whereas type 2 tumors showed amplification at two or three loci. Examination of the histoclinical features
of the amplified tumors showed two strikingly opposite data. First, type 1 tumors were more frequently lymph node–negative
tumors but were paradoxically associated with a poor prognosis. Second, type 2 tumors were more frequently lymph node–positive
tumors but were paradoxically associated with a good prognosis. Type 1 and type 2 showed different gene expression profiles.
No 20q13 gene could be associated with type 1 amplification, whereas several 20q13 genes were overexpressed in type 2 tumors.
Conclusions: Our results suggest that amplified tumors of types 1 and 2 are two distinct entities resulting from two different mechanisms
and associated to different prognosis.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - surgery</subject><subject>Cancer</subject><subject>Cellular Biology</subject><subject>chromosome 20</subject><subject>Chromosomes, Human, Pair 20 - genetics</subject><subject>Cluster Analysis</subject><subject>DNA microarrays</subject><subject>Female</subject><subject>Gene Amplification</subject><subject>Gene Expression Profiling</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Kaplan-Meier Estimate</subject><subject>Life Sciences</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Oligonucleotide Array Sequence Analysis - methods</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Reverse Transcriptase Polymerase Chain Reaction - methods</subject><subject>Survival Rate</subject><subject>Tissue Array Analysis - methods</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqFkcFu1DAQhi1UREvhEYpyAYlDWk_GTuzjNiptpZVAFZwtrzPedZVNtvZuC2-Pwy6UW08zGn8znvl_xs6AnwNIdQG8USUXWJ237V3JZVkh6lfsBKRsSqxqeZTzv8wxe5vSPecggIs37BhqpbXU-oTdfovjchhTSIUduuKaBiqufm4ipRTGocivPvRhWBajLyr-AFjO1ps--EBdcRnJpm3R2sFRTO_Ya2_7RO8P8ZT9-HL1vb0p51-vb9vZvHRC4bYUsvG191LkHQhQU-073UnLF7JDp3SuC-cXKBfaCwkdCSXqurFeK-dEo_GUfd7PXdnebGJY2_jLjDaYm9ncTLV8JYJu4BEy-2nPbuL4sKO0NeuQHPW9HWjcJVOrBvN0_SIIWteNEphBuQddHFOK5P-tANxMxphJdDOJbrIxhkszGZP7Phw-2C3W1D13HZzIwMcDYJOzvY9Z1ZCeOcWxqhT-d35Yrp5CJOP-6J8dIxvdykBlQBohEfE3PYGhyQ</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>GINESTIER, Christophe</creator><creator>CERVERA, Nathalie</creator><creator>CHAFFANET, Max</creator><creator>BIMBAUM, Daniel</creator><creator>BERTUCCI, Francois</creator><creator>FINETTI, Pascal</creator><creator>ESTEYRIES, Séverine</creator><creator>ESTERNI, Benjamin</creator><creator>ADDLAIDE, José</creator><creator>XERRI, Luc</creator><creator>VIENS, Patrice</creator><creator>JACQUEMIER, Jocelyne</creator><creator>CHARAFE-JAUFFRET, Emmanuelle</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-2674-3123</orcidid><orcidid>https://orcid.org/0000-0002-7477-3837</orcidid><orcidid>https://orcid.org/0000-0002-0157-0959</orcidid><orcidid>https://orcid.org/0000-0002-0286-1299</orcidid><orcidid>https://orcid.org/0000-0002-2344-1488</orcidid></search><sort><creationdate>20060801</creationdate><title>Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers</title><author>GINESTIER, Christophe ; CERVERA, Nathalie ; CHAFFANET, Max ; BIMBAUM, Daniel ; BERTUCCI, Francois ; FINETTI, Pascal ; ESTEYRIES, Séverine ; ESTERNI, Benjamin ; ADDLAIDE, José ; XERRI, Luc ; VIENS, Patrice ; JACQUEMIER, Jocelyne ; CHARAFE-JAUFFRET, Emmanuelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-457f6ff54168e139e6fd9d5a0b5d3c894164cfb35b9f451de484667af98cc4793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - surgery</topic><topic>Cancer</topic><topic>Cellular Biology</topic><topic>chromosome 20</topic><topic>Chromosomes, Human, Pair 20 - genetics</topic><topic>Cluster Analysis</topic><topic>DNA microarrays</topic><topic>Female</topic><topic>Gene Amplification</topic><topic>Gene Expression Profiling</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Kaplan-Meier Estimate</topic><topic>Life Sciences</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Oligonucleotide Array Sequence Analysis - methods</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Reverse Transcriptase Polymerase Chain Reaction - methods</topic><topic>Survival Rate</topic><topic>Tissue Array Analysis - methods</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GINESTIER, Christophe</creatorcontrib><creatorcontrib>CERVERA, Nathalie</creatorcontrib><creatorcontrib>CHAFFANET, Max</creatorcontrib><creatorcontrib>BIMBAUM, Daniel</creatorcontrib><creatorcontrib>BERTUCCI, Francois</creatorcontrib><creatorcontrib>FINETTI, Pascal</creatorcontrib><creatorcontrib>ESTEYRIES, Séverine</creatorcontrib><creatorcontrib>ESTERNI, Benjamin</creatorcontrib><creatorcontrib>ADDLAIDE, José</creatorcontrib><creatorcontrib>XERRI, Luc</creatorcontrib><creatorcontrib>VIENS, Patrice</creatorcontrib><creatorcontrib>JACQUEMIER, Jocelyne</creatorcontrib><creatorcontrib>CHARAFE-JAUFFRET, Emmanuelle</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GINESTIER, Christophe</au><au>CERVERA, Nathalie</au><au>CHAFFANET, Max</au><au>BIMBAUM, Daniel</au><au>BERTUCCI, Francois</au><au>FINETTI, Pascal</au><au>ESTEYRIES, Séverine</au><au>ESTERNI, Benjamin</au><au>ADDLAIDE, José</au><au>XERRI, Luc</au><au>VIENS, Patrice</au><au>JACQUEMIER, Jocelyne</au><au>CHARAFE-JAUFFRET, Emmanuelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2006-08-01</date><risdate>2006</risdate><volume>12</volume><issue>15</issue><spage>4533</spage><epage>4544</epage><pages>4533-4544</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: Amplification of chromosomal region 20q13 occurs in breast cancer but remains poorly characterized.
Experimental Design: To establish the frequency of 20q13 amplification and select the amplified cases to be studied, we used fluorescence in situ hybridization of bacterial artificial chromosome probes for three 20q13 loci ( MYBL2, STK6, ZNF217 ) on sections of tissue microarrays containing 466 primary carcinoma samples. We used Affymetryx whole-genome DNA microarrays
to establish the gene expression profiles of 20q13-amplified tumors and quantitative reverse transcription-PCR to validate
the results.
Results: We found 36 (8%) 20q13-amplified samples. They were distributed in two types: type 1 tumors showed ZNF217 amplification only, whereas type 2 tumors showed amplification at two or three loci. Examination of the histoclinical features
of the amplified tumors showed two strikingly opposite data. First, type 1 tumors were more frequently lymph node–negative
tumors but were paradoxically associated with a poor prognosis. Second, type 2 tumors were more frequently lymph node–positive
tumors but were paradoxically associated with a good prognosis. Type 1 and type 2 showed different gene expression profiles.
No 20q13 gene could be associated with type 1 amplification, whereas several 20q13 genes were overexpressed in type 2 tumors.
Conclusions: Our results suggest that amplified tumors of types 1 and 2 are two distinct entities resulting from two different mechanisms
and associated to different prognosis.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>16899599</pmid><doi>10.1158/1078-0432.CCR-05-2339</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-2674-3123</orcidid><orcidid>https://orcid.org/0000-0002-7477-3837</orcidid><orcidid>https://orcid.org/0000-0002-0157-0959</orcidid><orcidid>https://orcid.org/0000-0002-0286-1299</orcidid><orcidid>https://orcid.org/0000-0002-2344-1488</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2006-08, Vol.12 (15), p.4533-4544 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01431971v1 |
| source | Freely Accessible Journals |
| subjects | Antineoplastic agents Biological and medical sciences breast cancer Breast Neoplasms - genetics Breast Neoplasms - surgery Cancer Cellular Biology chromosome 20 Chromosomes, Human, Pair 20 - genetics Cluster Analysis DNA microarrays Female Gene Amplification Gene Expression Profiling Gynecology. Andrology. Obstetrics Humans In Situ Hybridization, Fluorescence Kaplan-Meier Estimate Life Sciences Mammary gland diseases Medical sciences Middle Aged Oligonucleotide Array Sequence Analysis - methods Pharmacology. Drug treatments Prognosis Reverse Transcriptase Polymerase Chain Reaction - methods Survival Rate Tissue Array Analysis - methods Treatment Outcome Tumors |
| title | Prognosis and Gene Expression Profiling of 20q13-Amplified Breast Cancers |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T09%3A31%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognosis%20and%20Gene%20Expression%20Profiling%20of%2020q13-Amplified%20Breast%20Cancers&rft.jtitle=Clinical%20cancer%20research&rft.au=GINESTIER,%20Christophe&rft.date=2006-08-01&rft.volume=12&rft.issue=15&rft.spage=4533&rft.epage=4544&rft.pages=4533-4544&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-05-2339&rft_dat=%3Cproquest_hal_p%3E68734669%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c483t-457f6ff54168e139e6fd9d5a0b5d3c894164cfb35b9f451de484667af98cc4793%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19967843&rft_id=info:pmid/16899599&rfr_iscdi=true |